In the News: Sino-US Scientific Cooperation; AstraZeneca Splits Its China Operation?; and Italy Limits Influence of Chinese Company

The U.S. government is debating whether to renew the U.S.-China Science and Technology Agreement; AstraZeneca plans to break up its business in China and list it separately in Hong Kong; the Italian government applies Golden Power regulations to limit the influence of China's Sinochem on tyremaker Pirelli

7 minute readJune 21, 2023 at 02:53 AM

Clarence Lee

In the News: Sino-US Scientific Cooperation; AstraZeneca Splits Its China Operation?; and Italy Limits Influence of Chinese Company

Looker_Studio/Adobe Stock

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)